.webp?width=217&height=60&name=Screenpoint-Med%20(1).webp "Screen Point Medical")
ScreenPoint Medical Acquires Biomediq A/S to Expand Breast Cancer Risk Assessment Capabilities
ScreenPoint Medical Acquires Biomediq A/S to Expand Breast Cancer Risk Assessment Capabilities
Deal brings enhanced capabilities for ScreenPoint’s industry-leading Transpara Breast AI.
January 08, 2025
Transpara Announces New FDA Clearance at RSNA 2024
.png)
Transpara Announces New FDA Clearance at RSNA 2024
SPM Showcases Innovative FDA Cleared Capabilities including Breast Density Assessment and Temporal Comparison to Elevate Radiologist Performance
December 02, 2024
Transpara Improves Cancer Detection by Decreasing False Negative Cancers
.png)
Transpara Improves Cancer Detection by Decreasing False Negative Cancers
Transpara Accurately Identified Half of False Negative Cancers – all Invasive, and Often in Dense Breasts – in a Large Retrospective Study
November 19, 2024
Transpara may have detected Karin Boxem’s breast cancer years earlier, potentially preventing her from a mastectomy.
.png)
Transpara may have detected Karin Boxem’s breast cancer years earlier, potentially preventing her from a mastectomy.
Karin Boxem reflects on how AI could have changed her cancer journey.
November 12, 2024
ScreenPoint Medical Leadership Transition: Pieter Kroese Confirmed as CEO
.png)
ScreenPoint Medical Leadership Transition: Pieter Kroese Confirmed as CEO
Pieter Kroese appointed as the Chief Executive Officer of ScreenPoint Medical, effective April 25, 2024.
April 05, 2024
ScreenPoint Medical Deploys Transpara® Breast AI at Johns Hopkins to Improve Cancer Detection
.png)
ScreenPoint Medical Deploys Transpara® Breast AI at Johns Hopkins to Improve Cancer Detection
Transpara implemented for clinical use by key thought leaders in radiology and breast imaging.
March 12, 2024